Evidence map›Paper›PMID 39376720›Full record

ArticleJournal of surgical case reports2024

Follow-up report on pulmonary mucosa-associated lymphoma in a patient with von Hippel-Lindau disease.

Bukola A Olarewaju, Judy B Tejon, Mayowa A Osundiji

Abstract readCase Reports
In one paragraph

Article in Journal of surgical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bukola A OlarewajuSchool of Science and Engineering, University of Dundee, Nethergate, Dundee DD1 4HN, United Kingdom.
Judy B TejonDepartment of Clinical Genomics, Mayo Clinic, East Shea Blvd, Scottsdale, AZ 85259, United States.
Mayowa A OsundijiDepartment of Clinical Genomics, Mayo Clinic, East Shea Blvd, Scottsdale, AZ 85259, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.

Indexed as

lymphomatumorvon Hippel–Lindau

Identifiers

PMID39376720
PMCPMC11456818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.